Matches in Nanopublications for { ?s ?p "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP662090.RAB3S2Fhj6mwoHrJdeT1gjWzXHhr_y9iWHX700VU1KA8A130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP662090.RAB3S2Fhj6mwoHrJdeT1gjWzXHhr_y9iWHX700VU1KA8A130_provenance.
- NP651019.RAdjZPeBDlKL_DQfbXQmJ_cuvIOyADNsC09Q6m7dbqyXc130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651019.RAdjZPeBDlKL_DQfbXQmJ_cuvIOyADNsC09Q6m7dbqyXc130_provenance.
- NP708198.RAReMBJcL2NHmLvoI5o3L9TSP9P91npNiRdVRHyVBXbt4130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP708198.RAReMBJcL2NHmLvoI5o3L9TSP9P91npNiRdVRHyVBXbt4130_provenance.
- NP362166.RANeRyimaIitGWEiLF2OHhTB1GsoEkv_mTTy1FRbmXrYU130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP362166.RANeRyimaIitGWEiLF2OHhTB1GsoEkv_mTTy1FRbmXrYU130_provenance.
- NP893786.RA98Z1fkFHo18z9utQjTRyYM6sTDWz15tfS8bZ58a70Tk130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893786.RA98Z1fkFHo18z9utQjTRyYM6sTDWz15tfS8bZ58a70Tk130_provenance.
- NP939471.RAzxHtvI3bccewY2nbs2u7XLtrwBhzbgC-jOyrhmUuilA130_assertion description "[We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive SM/mast cell leukemia, 19/22) whereas only 3/12 (25%) indolent SM/smoldering SM patients carried one additional mutation each (U2AF1, SETBP1, CBL) (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939471.RAzxHtvI3bccewY2nbs2u7XLtrwBhzbgC-jOyrhmUuilA130_provenance.